 wrap-up in-lin sale guidanc
messag neutral today vs
follow earn report in-lin sale key driver trulic diabet
taltz immunolog disord fall short our/consensu expect management
confid growth key categori sustain guidanc unchang
mgmt guidanc broadli line estim maintain neutral
lower estim touch diabet immunolog reflect price dynam
report sale y/i growth key product includ trulic
taltz basaglar verzenio repres global volum growth global sale
grew volum growth off-set price declin management express confid
perform key growth driver note patient mix reimburs price
dynam contribut price declin across portfolio highlight impact
insulin taltz trulic specif taltz trulic management note
perform qtr impact increas util patient afford program
primarili insulin taltz trulic sequenti volum growth impact
rebat discount adjust higher contract rebat comment
today result consist financi guidanc take
diabet taltz number reflect increas competit net-net rais sale
due larg higher expect sale ciali lower sale
better reflect price competit pressur mainli taltz
slow emgal ramp reflect free drug impact competit
emgal share trend strong qtr new prescript share report
sale well expect highlight net price dynam
emgalitu class given disappoint sale vs consensu sale
report aimovig nc novn-swx buy chf
management comment expect improv reimburs base trend
exit quarter given free drug dynam impli trajectori net price
improv reduc near-term emgal estim
respect out-year sale reduc
catalyst year-end management highlight upcom medic meet includ
ada american diabet associ provid detail result trulic
rewind studi investor call ada post-rewind present upcom
american societi clinic oncolog confer present data erk
inhibitor program cyramza data egfr mutation-posit metastat nsclc relay
studi clinic catalyst remaind year includ trulic altern dose
ret-inhibitor registr phase studi nsclc thyroid cancer jardianc chf
exercis abil studi taltz head head guselkumab tremfya cs
compani
revenu provid recast sale
adj ep provid recast ep exclud
page analyst certif import disclosur
valuat risk
fair valu rang reflect forecast sale profit
use larg pharmaceut compani discount rate termin
upsid risk valuat includ trulic jardianc sale meaning
estim better expect oper leverag
downsid risk includ sustain price pressur diabet immunolog
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
